Nektar Therapeutics (NKTR): A Case For Going Higher

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $0.69 and fluctuated between $0.7644 as its day high and $0.6521 as its day low. The current market capitalization of Nektar Therapeutics is $130.68M. A total of 1.78 million shares were traded on the day, compared to an average of 1.20M shares.

Insider Activity

Insider trades can also provide insight into a stock’s future direction. During the recent three months, NKTR has seen 0 BUY and 3 SELL insider trades, representing the acquisition of 0 and the disposition of 36,702 shares. Over the last 12 months, there were 0 BUYs and 16 SELLs from insiders. Insiders purchased 0 shares during that period but sold 198,698.

In the most recent transaction, ROBIN HOWARD W sold 19,877 shares of NKTR for 0.49 per share on Nov 17. After the transaction, the President & CEO now owns 899,922 company shares. In a previous transaction on Nov 17, Zalevsky Jonathan sold 9,646 shares at 0.49 per share. NKTR shares that Chief R&D Officer owns now total 274,039.

Among the insiders who sold shares, Wilson Mark Andrew disposed of 7,179 shares on Nov 17 at a per-share price of $0.49. This resulted in the Chief Legal Officer holding 243,780 shares of NKTR after the transaction. In another insider transaction, Curet Myriam sold 4,359 shares at $0.69 per share on Sep 18. Company shares held by the Director now total 27,418.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for NKTR in the last 3 months, the mean price target is $2.75 with high estimates of $5.00 and low estimates of $0.50. In terms of 52-week highs and lows, NKTR has a high of $3.16 and a low of $0.41.

As of this writing, NKTR has an earnings estimate of $Nektar Therapeutics per share for the current quarter. EPS was calculated based on a consensus of Nutrien Ltd. estimates, with a high estimate of $Nature’s Sunshine Products, Inc per share and a lower estimate of $Nkarta, Inc.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. NKTR’s latest balance sheet shows that the firm has $733.96M in Cash & Short Term Investments as of fiscal 2021. There were $143.18M in debt and $85.20M in liabilities at the time. Its Book Value Per Share was $0.84, while its Total Shareholder’s Equity was $679.51M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NKTR is Buy with a score of 2.60.

Most Popular

Related Posts